Gordon Van Slyke: “I am a Trial Participant for the New Alzheimer’s Drug Lecanemab.

Join Being Patient Wednesday, January 11th at 9 am PT/ 12pm ET for a live conversation with Gordon Van Slyke about his experience in the lecanemab trial and his reaction to the recent news of the drug’s FDA approval under the name Leqembi.

Gordon Van Slyke’s mother and sister both passed away of early onset Alzheimer’s when they were in their early 60s. When he decided to participate in Alzheimer’s research — specifically the phase 3 drug trials for Eisai and Biogen’s new monoclonal antibody drug lecanemab — it was this family history that motivated him. Learn all about this experience by attending this Live Talk!